Camurus Management

Management criteria checks 4/4

Camurus' CEO is Fredrik Tiberg, appointed in Jan 2003, has a tenure of 21.33 years. total yearly compensation is SEK12.06M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 2.78% of the company’s shares, worth SEK797.12M. The average tenure of the management team and the board of directors is 6.6 years and 4 years respectively.

Key information

Fredrik Tiberg

Chief executive officer

kr12.1m

Total compensation

CEO salary percentage	49.1%
CEO tenure	21.3yrs
CEO ownership	2.8%
Management average tenure	6.6yrs
Board average tenure	4yrs

Recent management updates

Recent updates

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Apr 30

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Dec 09

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Sep 09

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Jun 10

CEO Compensation Analysis

How has Fredrik Tiberg's remuneration changed compared to Camurus's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr12m	n/a	kr431m
Sep 30 2023	n/a	n/a	kr460m
Jun 30 2023	n/a	n/a	kr408m
Mar 31 2023	n/a	n/a	kr115m
Dec 31 2022	kr10m	kr6m	kr56m
Sep 30 2022	n/a	n/a	kr28m
Jun 30 2022	n/a	n/a	-kr13m
Mar 31 2022	n/a	n/a	-kr69m
Dec 31 2021	kr10m	kr6m	-kr90m
Sep 30 2021	n/a	n/a	-kr142m
Jun 30 2021	n/a	n/a	-kr156m
Mar 31 2021	n/a	n/a	-kr128m
Dec 31 2020	kr10m	kr5m	-kr167m
Sep 30 2020	n/a	n/a	-kr174m
Jun 30 2020	n/a	n/a	-kr216m
Mar 31 2020	n/a	n/a	-kr284m
Dec 31 2019	kr8m	kr5m	-kr290m
Sep 30 2019	n/a	n/a	-kr305m
Jun 30 2019	n/a	n/a	-kr286m
Mar 31 2019	n/a	n/a	-kr266m
Dec 31 2018	kr8m	kr5m	-kr235m
Sep 30 2018	n/a	n/a	-kr200m
Jun 30 2018	n/a	n/a	-kr208m
Mar 31 2018	n/a	n/a	-kr187m
Dec 31 2017	kr6m	kr4m	-kr191m

Compensation vs Market: Fredrik's total compensation ($USD1.10M) is about average for companies of similar size in the Swedish market ($USD961.92K).

Compensation vs Earnings: Fredrik's compensation has been consistent with company performance over the past year.

CEO

Fredrik Tiberg (60 yo)

21.3yrs

Tenure

kr12,056,000

Compensation

Mr. Fredrik Tiberg has been Independent Director of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. Mr. Tiberg serves as Chief Executi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fredrik Tiberg	President	21.3yrs	kr12.06m	2.78% SEK 797.1m
Jon U. Alonso	Chief Financial Officer	2.3yrs	no data	0.0025% SEK 723.4k
Torsten Malmstrom	Chief Technology Officer	11.3yrs	no data	0.081% SEK 23.3m
Rein Piir	Vice President of Investor Relations	9.3yrs	no data	no data
Maria Lundqvist	Global Head of Human Resources	3.1yrs	no data	no data
Markus Johnsson	Senior Vice President of R&D	no data	no data	0.036% SEK 10.5m
Fredrik Joabsson	Chief Business Development Officer	5.3yrs	no data	0.087% SEK 24.9m
Richard Jameson	Chief Commercial Officer	7.9yrs	no data	0.051% SEK 14.5m
Alberto Pedroncelli	Chief Medical Officer	less than a year	no data	no data

6.6yrs

Average Tenure

57yo

Average Age

Experienced Management: CAMX's management team is seasoned and experienced (6.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fredrik Tiberg	President	22.3yrs	kr12.06m	2.78% SEK 797.1m
Ole Vahlgren	Independent Director	4yrs	kr375.00k	0.017% SEK 5.0m
Jakob Lindberg	Independent Director	3yrs	kr350.00k	no data
Per-Olof Wallstrom	Independent Chairman of the Board	14.3yrs	kr750.00k	0.18% SEK 50.9m
Behshad Sheldon	Independent Director	6yrs	kr350.00k	0.0017% SEK 499.5k
Kerstin Strinnholm	Independent Director	8.8yrs	kr375.00k	0.047% SEK 13.4m
Hege Hellstrom	Independent Director	4yrs	kr375.00k	0.0056% SEK 1.6m
Stefan Persson	Director	2yrs	kr375.00k	0.0054% SEK 1.5m
Erika Johnsson	Director	less than a year	kr450.00k	0.0011% SEK 304.3k

4.0yrs

Average Tenure

60yo

Average Age

Experienced Board: CAMX's board of directors are considered experienced (4 years average tenure).

Camurus Management

Management criteria checks 4/4

Key information

Recent management updates

Camurus AB (Publ) Announces Board Resignations

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

President exercised options to buy kr86m worth of stock.

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

President recently sold kr23m worth of stock

Recent updates

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305

Camurus AB (Publ) Provides Earnings Guidance for the Year 2022

Price target increased to kr283

Camurus AB (publ), Annual General Meeting, May 10, 2023

Camurus AB (publ) to Report Fiscal Year 2022 Final Results on Mar 30, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Raises Operating Result Guidance for the Full Year 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Vice President exercised options and sold kr178k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Camurus AB (Publ) Elects Stefan Persson as New Board Member

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Full year 2021 earnings: EPS and revenues miss analyst expectations

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Provides Earnings Guidance for the Fiscal Year 2022

Camurus Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Pants with Genetic Obesity Disoisorder

Forecast breakeven date pushed back to 2022

Camurus AB Announces Braeburn Receives New Complete Response Letter for Brixadi in the US

We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth

Insider recently sold kr392k worth of stock

The European Medicines Agency Accepts Camurus's Application to Extend the Buvidal Indication to Include Treatment of Chronic Pain